Zacks Investment Research upgraded shares of ALBANY MOL RSCH (AMRI) from UNDERPERFORM to NEUTRAL on July 10, 2012, with a target price of $2.80.
Albany Molecular Research is an integrated provider of drug discovery and development, chemistry research and manufacturing services. They offer services traditionally provided by chemistry divisions within pharmaceutical and biotechnology companies, including drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. Recently, they expanded their service offerings to include commercial manufacturing through their strategic relationship with and investment in Organichem Corporation.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ALBANY MOL RSCH (AMRI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment